Although the specific effects of SARS-CoV-2 infection on the progression of anti-MDA5+ DM or concomitant MAS remain unclear, evidence suggests that SARS-CoV-2 may exacerbate DM by triggering a predisposed inflammatory cascade in susceptible individuals. The gene discussed is IFIH1; the disease is dermatomyositis.